Common side effects include pain and redness around the site of injection (up to 50% of recipients). A small percentage of people develop a mild fever. A small proportion of people develop a severe allergic reaction. In 2016 Health Canada warned of an increased risk of anemia or hemolysis in people treated with eculizumab (Soliris). The highest risk was when individuals "received a dose of Soliris within 2 weeks after being<unk> ted with Bexsero". Despite initial concerns about Guillain-Barré syndrome, subsequent studies in 2012 have shown no increased risk of GBS after<unk>  conjugate<unk> tion.
Meningococcal vaccine
Measles vaccine
Typhoid vaccine
Pertussis vaccine
Polio vaccine
Tetanus vaccine
Typhus vaccine
Mumps vaccine